Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT03183505 Completed - Clinical trials for Major Depressive Disorder

Comparison of Anyu Peibo With Placebo in Treatment of MDD,Ⅱb

Start date: June 30, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression. And to provide some scientific evidence for protocol designing in following phase Ⅲ clinical trial.

NCT ID: NCT03181529 Completed - Clinical trials for Major Depressive Disorder

Effects of Psilocybin in Major Depressive Disorder

Start date: August 10, 2017
Phase: Phase 2
Study type: Interventional

The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. The primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.

NCT ID: NCT03177304 Completed - Depression Clinical Trials

Web Based Therapist Training in Interpersonal Psychotherapy for Depression

Start date: December 1, 2014
Phase: N/A
Study type: Interventional

The National Institutes of Mental Health has identified the use of empirically based mental health treatments (i.e., treatments with research supporting efficacy) as a priority, yet there is a shortage of clinicians trained in these approaches. This study develops an on-line therapist training program for Interpersonal Psychotherapy (IPT), a particularly well-researched yet particularly little disseminated, empirically based treatment, in order to facilitate wider dissemination of this approach.

NCT ID: NCT03169543 Completed - Clinical trials for Depression, Unipolar

Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

From 40 to 60% of patients with depression experience a rapid and significant improvement of mood with one night of sleep deprivation (SD). The neural mechanisms underlying this effect have not been elucidated. Recent advances in functional neuroimaging have provided new opportunities to investigate state changes in regional brain function, along with a better understanding of the neural networks affected by depression and SD. Here we propose to study a group of N=48 antidepressant-free male and female patients with current depression symptom and N=12 healthy controls with no history of mood disorders before and after SD to provide mechanistic insight into the neural substrates underlying the antidepressant effects of SD. We hypothesize that SD-induced concurrent functional activity and connectivity changes in multiple brain networks related to different depressive symptom dimensions including emotion regulation, attention, arousal, self-referential, and reward processing will underlie the rapid and transient antidepressant effects of SD. Using an ABA design, multimodal brain imaging along with more traditional electroencephalographic (EEG) and neurobehavioral testing data will be acquired at baseline after normal sleep, during one night of total SD, and after one night of recovery sleep using a 5-day in laboratory protocol during which subjects will be continuously monitored by trained staff.

NCT ID: NCT03167307 Completed - Depression Clinical Trials

The Omega-3 Fatty Acid Paediatric Depression Trial

Omega-3-pMDD
Start date: April 28, 2017
Phase: Phase 3
Study type: Interventional

This study investigates the therapeutic efficacy and safety of omega-3 fatty acids rich in eicosapentaenoic acid / docosahexaenoic acid in pediatric depression in a nine months double-blind multi-centre study in 220 children and adolescents between 8 and 17 years of age. Inflammatory and bioactive lipid markers as predictors of response are evaluated. The relationship between omega-3 fatty acids with psychopathology, illness course and cognitive parameters will be further investigated.

NCT ID: NCT03165513 Completed - Clinical trials for Depressive Disorder, Major

Dialogue to Empower Traditional and Faith Healers to Deliver mhGAP-IG Adapted Psychosocial Interventions in Kenya

Dialogue
Start date: July 1, 2014
Phase: N/A
Study type: Interventional

The project aimed to create a dialogue between the informal sector (traditional and faith healers) and the formal sector (trained health care workers) in order to increase synergy and communication between the two systems, by minimizing any harmful practices and enhancing complementary practices. The informal sector will also be trained on how to use WHO mhGAP-IG component on depression for routine screening in order to ameliorate functional and social outcomes and refer complicated cases to the formal sector for biological interventions

NCT ID: NCT03163940 Completed - Depression Clinical Trials

Laughter Yoga Intervention for People With Major Depressive Disorder

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The present study will adopt a non-blinded parallel-group randomized controlled trial design that involves a Laughter Yoga group (intervention) and a treatment-as-usual group (Control). It aims to determine the feasibility of using LY intervention on patients with Major depressive disorder (MDD), and also to evaluate the potential effect of the intervention on comorbid depression, anxiety and stress for these patients. It is hypothesized that, LY group, as compared to the TAU group, will have significantly lower symptoms of depression, anxiety and stress, but greater improvements in self-reported mental health/physical health-related quality of life immediately post intervention and at 3 months' follow-up.

NCT ID: NCT03157050 Completed - Depression Clinical Trials

Intravenous Iron May Increase Depression Among Hemodialysis Patients

Start date: January 14, 2016
Phase: N/A
Study type: Observational

the aim of this study is to assess whether increased ferritin after intravenous iron therapy will lead to increased prevalence of major depression among treated patients.

NCT ID: NCT03156556 Completed - Clinical trials for Major Depressive Disorder

Improving Access to the Treatment of Anxiety and Depression Among Young Adults

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

Anxiety and depression represent the most common mental health problems. Unfortunately, only a minority of people in need will seek or access traditional mental health services. Access to traditional psychological care is even more challenging for linguistic minorities as well as for people living in rural areas and for young adults - a group that has the highest rate of anxiety and depression but the lowest rate of consulting traditional services.Telepsychotherapy can facilitate access to effective psychological care as done in Australia where the government has been offering an evidence-based 8-week online therapy program called the Wellbeing Course. This online course helps people manage worry, stress, anxiety and depression. It has been evaluated in several clinical trials and successfully implemented as an Australian national treatment service. Its transdiagnostic nature, and the fact that the guidance of a clinician is not required for an efficient and safe administration and maintenance of therapeutic gains make it not only a viable option, but also an easily accessible fist line intervention. More recently, findings from a feasibility study conducted by our research laboratory have supported the efficacy of a French-Canadian translation among French-speaking minorities in New-Brunswick. A version of the Wellbeing Course for young adults has been developed called the Mood Mechanic Course. Empirical support has been obtained. This study is a feasibility open trial, the first phase of a 3-phase research program designed to implement a French-Canadian translation of the Mood Mechanic Course in New Brunswick targeting groups for which access to traditional services has been most problematic: youth (18 to 25 years old), people living in rural areas and linguistic minorities. The course is an 8-week week program based on principles of cognitive behaviour therapy. It includes five online lessons, do-it-yourself exercises, case stories, and additional resources on different topic such as sleep hygiene. Twenty young adults will be recruited across New Brunswick among French-Canadian minority communities. Self-report measures assessing anxiety and depression will be administered pre/post treatment and at a 3-month follow-up. It is expected that the course will help overcome barriers in help seeking to improve the mental health of our communities.

NCT ID: NCT03156504 Completed - Major Depression Clinical Trials

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

Bio-K
Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a non-FDA approved reason (depression).